Zomedica Corp. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a company at a critical inflection point. On one hand, the normalization of the P&L—following a massive non-cash impairment charge in the prior year—reveals a business that is growing its revenue and tightening its operational belt. The shift toward contract manufacturing and new diagnostic products indicates a strategic evolution that could broaden the company's market appeal. However, the gap between revenue and operating expenses remains wide, and the decline in gross margin indicates a lack of pricing power or increased manufacturing inefficiencies. Investors must weigh the impressive revenue momentum against the reality of continued cash burn and the risk of future dilution. The ultimate success of the turnaround depends on whether Zomedica can convert its increased sales volume into actual operating leverage before its liquid reserves are depleted.